IRB and IBC Review for Gene Therapy and Cell Therapy Trials

Gene therapy and cell therapy studies require thorough ethical and biosafety oversight due to their technical complexity and potential risks to participants, staff, and the environment. Subject to applicable rules and regulations of the United States, two critical layers of review are essential: Institutional Review Board (IRB) review, which protects human research participants and ensures ethical study conduct, and Institutional Biosafety Committee (IBC) review, which focuses on the containment and safe use of engineered genetic materials, gene editing products, and genetically modified organisms. Together, these reviews are crucial for safe, responsible, and credible research. 

Why Are IRB and IBC Reviews Needed? 

In the U.S., IRB review is broadly required for human clinical trials to ensure informed consent, ethical study design, and the protection of participants in accordance with federal rules such as the FDA’s Good Clinical Practice (GCP) guidelines and the Common Rule (45 CFR 46). Additionally, IBC review is recommended or required specifically for clinical trials of investigational products that contain engineered DNA or RNA, or that are capable of permanently modifying DNA in a participant’s cells (i.e., gene editing products). Examples include virally-vectored vaccines, gene therapies, CRISPR-enabled gene editors, and genetically modified cell therapies. The IBC evaluates research practices, biosafety protocols, and risk mitigation strategies, guided primarily by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. 

Cell and gene therapy trials introduce new challenges because interventions may present risks not only to the participants but also to clinical staff, the community, and the environment. This dual risk is why both IRB and IBC oversight are required for relevant clinical trials before a study begins. 

Dual Oversight: How Reviews Work Together 

Historically, IRB and IBC reviews have often been conducted through independent, sometimes sequential, processes. This can result in redundant documentation, fragmented communication, and prolonged study start-up times — especially problematic for cell and gene therapy trials, where approval timelines and regulatory requirements are already demanding. 

To overcome these hurdles, a parallel or coordinated review is highly effective. The IRB focuses on participant protection — reviewing informed consent procedures, eligibility criteria, and risk minimization measures. Simultaneously, the IBC reviews the handling of biohazards to ensure the safety of personnel, the public, and the environment. IRB oversight is required for the duration of a clinical trial; IBC oversight is required for as long as administration/dosing of the gene transfer product proceeds per protocol.  

The Review Journey at WCG: Key Steps 

For human gene transfer research, sponsors and CROs have the option to use WCG IRB Services or IBC Services, or both. If you would like to learn more about the difference between IRB and IBC review, check out the article “IRB vs. IBC: What’s the Difference?” 

When either committee is conducting reviews, it must review in line with the requirements of the NIH Guidelines, including assessment of facilities, equipment, training, procedures, biocontainment practices, and biosafety level assignment, with approval of research determined by a vote of the convened committee.   

Local IBC Review	WCG Central IBC Review
Each site has its own forms and procedures for bringing research proposals before the committee.	All sites may submit using a streamlined form.
There is usually a regular deadline for submission.	All submissions are accepted on a rolling basis.
Committee typically meets once a month.	IBC convenes on demand for each investigator as soon as possible when submission is complete.
Study staff must extract molecular and microbiological information from clinical trial documents to format responses to local submission forms.	WCG analysts extract all relevant information from study-level documents to apply product risk assessments to all sites.
Study staff must develop NIH-compliant biosafety SOPs.	WCG analysts prepare study-specific SOP templates for distribution to all sites, which may be updated for local context.
Site is responsible for recruiting, registering, and maintaining roster with the NIH Office of Science Policy.	WCG manages all committee-related registration, recruitment, and annual renewal tasks on behalf of the site.

Challenges for Sites and Sponsors 

Site staff and sponsors face growing complexity with cell and gene therapy trials — protocols are evolving, regulatory expectations are high, and compliance failures can delay research or threaten participant safety. Common challenges include: 

• Navigating overlapping timelines and documentation for IRB and IBC reviews. 

• Managing communication between distinct oversight committees. 

• Staying current with rapidly changing regulatory guidance. 

• Ensuring that staff training, biosafety practices, and ethical standards are aligned and up to date. 

WCG’s Role: Support with IRB and IBC Services 

WCG provides advisory support, operational expertise, and technology solutions to help research sites, sponsors, and study teams manage the IRB and IBC review process efficiently and compliantly. 

Integrated Review Support: 

WCG’s IRB and IBC services are designed to streamline the review pathway. Through integrated workflows, centralized communication, and dedicated regulatory specialists, WCG helps you move through IRB and IBC review in parallel, reducing duplicate submissions and accelerating study timelines. 

Expert Guidance: 

With deep domain expertise, WCG supports sites in interpreting regulatory requirements, submitting complete and compliant documentation, and responding to committee queries. WCG brings experience navigating complicated biosafety and ethical challenges specific to cell and gene therapy. 

Ongoing Compliance: 

WCG helps manage amendment tracking, continuing reviews, and communication updates, providing tools and resources that keep approvals current and documentation aligned with institutional, federal, and sponsor requirements. 

Support for Sites and Institutions: 

For sites and institutions wishing to take advantage of IBC services, WCG can quickly establish a new IBC and maintain its registration with the NIH. WCG administers IBCs on behalf of small independent sites, site networks, and leading academic medical centers. 

Outcome: 

The ultimate goal of WCG’s support is to enable more predictable, efficient, and compliant research for all stakeholders, supporting the safe, ethical, and rapid advancement of cell and gene therapy studies. 

Frequently Asked Questions 

What is required for gene therapy trials? 

IRB review is required for research involving human subjects, and the type is dependent on a multitude of factors, including the level of risk, vulnerability of the participant population, and additional aspects. Follow GCP and Common Rule guidance for IRB review requirements. IBC review is dependent on the nature of the research and NIH funding considerations. Follow NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules for IBC review requirements. 

Do sites need an IBC if none exists in-house? 

Yes. Sites conducting research subject to IBC oversight requirements outlined by the NIH are required to receive approval from an IBC established specifically for the institution. This can be done by partnering with a qualified external IBC administrator, like WCG, to meet NIH and institutional requirements. 

How does coordinated review improve efficiency? 

Parallel or integrated IRB and IBC review streamlines communication, cuts down on duplicate paperwork, and accelerates start-up. 

How to get started? 

Submit a protocol and required documents to both the IRB and IBC (or through a service like WCG’s IRB+ and IBC+). Maintain ongoing compliance, address amendments promptly, and lean on regulatory and operational support as needed. 

Start Your Gene Therapy Review With WCG 

The IRB and IBC review process is essential for safeguarding participants, research personnel, and the community in complex cell and gene therapy research. Your trial deserves a review partner with the expertise, infrastructure, and regulatory depth to handle what makes gene therapy and cell therapy uniquely complex. WCG’s combined IRB and IBC review is the only solution of its kind — built to keep your research moving and ensure compliance at every stage.